Aptinyx lands $70 mln Series B

Aptinyx Inc, a developer of treatments for neurologic disorders, has closed $70 million in Series B financing. Bain Capital Life Sciences led the round with participation from other investors that included Adage Capital, Agent Capital, HBM Healthcare Investments, Nan Fung Life Sciences, Partner Fund Management, Rock Springs Capital, New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Osage University Partners, Adams Street Partners and Beecken Petty O'Keefe & Company.

ManagersNorth AmericaUSHealthcareBriefs